CYCLACEL PHARMACEUTICALS - CYCC 6 PERP (CYCCP) Stock News
NASDAQ:CYCCP - Nasdaq - US23254L2079 - Currency: USD
CYCCP Latest News, Press Relases and Analysis
Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar
David Lazar agrees to invest $3.1 million in Preferred Stock and becomes Interim CEO...
Mentions: CYCC
Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar
David Lazar agrees to invest $3.1 million in Preferred Stock and becomes Interim CEO
Mentions: CYCC
Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs
BERKELEY HEIGHTS, N.J., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP;
Mentions: CYCC
Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs
Mentions: CYCC
Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds
Mentions: CYCC
Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds
BERKELEY HEIGHTS, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP;
Mentions: CYCC
Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds
Mentions: CYCC
Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds
BERKELEY HEIGHTS, N.J., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP;
Mentions: CYCC
Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update
BERKELEY HEIGHTS, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP;
Mentions: CYCC
Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update
Mentions: CYCC
Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule
CYCLACEL PHARMACEUTICALS ANNOUNCES THAT NASDAQ GRANTED AN EXTENSION TO REGAIN COMPLIANCE WITH THE EQUITY STANDARD RULE...
Mentions: CYCC
Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule
Mentions: CYCC
Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium
NEW CLINICAL DATA FROM ONGOING, PHASE 2 STUDY OF ORAL FADRACICLIB AT THE 2024 ENA SYMPOSIUM. Patients preselected for CDKN2A and/or CDKN2B abnormalities...
Mentions: CYCC
Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium
- Interim data for fadraciclib monotherapy in patients with advanced solid tumors preselected for CDKN2A and/or CDKN2B abnormalities -
Mentions: CYCC
Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium
Initial safety and efficacy data from fadraciclib monotherapy in patients with advanced solid tumors preselected for CDKN2A and/or CDKN2B abnormalities ...
Mentions: CYCC
Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium
Initial safety and efficacy data from fadraciclib monotherapy in patients with advanced solid tumors preselected for CDKN2A and/or CDKN2B abnormalities
Mentions: CYCC
Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study
Cyclacel announces completion of enrollment in the biomarker-enriched cohort of its Phase 2 study - Patients are preselected for C...
Mentions: CYCC
Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study
Mentions: CYCC
Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference
Cyclacel to participate at the H.C. Wainwright 26th Annual Global Investment Conference...
Mentions: CYCC
Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference
Mentions: CYCC
Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting Letter
Cyclacel timely appeals against Nasdaq delisting letter. Delisting stayed until Nasdaq hearing panel determination...
Mentions: CYCC
Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting Letter
Delisting or suspension action stayed pending the issuance of a final decision
Mentions: CYCC
Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update
Cyclacel provides Q2 2024 financial results and business update on fadraciclib precision medicine strategy...
Mentions: CYCC
Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update
Mentions: CYCC
Cyclacel Pharmaceuticals to Release Second Quarter 2024 Financial Results
BERKELEY HEIGHTS, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP;
Mentions: CYCC
Cyclacel Pharmaceuticals to Release Second Quarter 2024 Financial Results
Mentions: CYCC
Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions
NOTICE OF INTENTION TO GRANT OF NEW EUROPEAN PATENT COVERING PLOGOSERTIB PHARMACEUTICAL COMPOSITIONS - Lengthens Patent Exclusivity to August 2040...
Mentions: CYCC
Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions
Lengthens Patent Exclusivity of Plogosertib until August 2040
Mentions: CYCC
Cyclacel’s Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting
- Novel CDK2/9 inhibitor fadraciclib induces anaphase catastrophe, a novel cancer-specific mechanism of action - BERKELEY HEIGHTS,...
Mentions: CYCC
Cyclacel’s Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting
Mentions: CYCC
Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update
Mentions: CYCC
Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results
BERKELEY HEIGHTS, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP;
Mentions: CYCC
Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results
Mentions: CYCC
Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules
BERKELEY HEIGHTS, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP;
Mentions: CYCC
Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules
Mentions: CYCC
Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
BERKELEY HEIGHTS, N.J., April 30, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP;
Mentions: CYCC
Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Mentions: CYCC